Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia

Journal of Experimental Medicine

Volumn 213, Issue 4, 2016, Pages 483-497

  Boutzen, Héléna ^a,b,c   Saland, Estelle ^a,b   Larrue, Clément ^a,b   de Toni, Fabienne ^a,b   Gales, Lara ^d,e,f   Castelli, Florence A ^g   Cathebas, Mathilde ^a,b   Zaghdoudi, Sonia ^a,b   Stuani, Lucille ^a,b   Kaoma, Tony ^h   Riscal, Romain ^i,j,k   Yang, Guangli ^l   Hirsch, Pierre ^m,n,o   David, Marion ^a,b   De Mas Mansat, Véronique ^a,b,c   Delabesse, Eric ^a,b,c   Vallar, Laurent ^h   Delhommeau, François ^m,n,o   Jouanin, Isabelle ^p   Ouerfelli, Ouathek ^l   Le Cam, Laurent ^i,j,k   Linares, Laetitia K ^i,j,k   Junot, Christophe ^g   Portais, Jean Charles ^d,e,f   Vergez, François ^a,b,c   Récher, Christian ^a,b,c   Sarry, Jean Emmanuel ^a,b   more..

^a INSERM   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

^d UNIVERSITÉ PAUL SABATIER   (France)

^e UMR792 INGÉNIERIE DES SYSTÈMES BIOLOGIQUES ET DES PROCÉDÉS   (France)

^f CNRS   (France)

^g Institut National de la Recherche Agronomique   (France)

^h LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

ⁱ INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTPELLIER   (France)

^j UNIV MONTPELLIER   (France)

^k CENTRE VAL D AURELLE   (France)

^l MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^m SORBONNE UNIVERSITÉ   (France)

ⁿ CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^o HÔPITAL SAINT ANTOINE   (France)

^p TOXALIM RESEARCH CENTRE IN FOOD TOXICOLOGY   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYGLUTARIC ACID; CD14 ANTIGEN; CD15 ANTIGEN; DNA METHYLTRANSFERASE 3A; INTERFERON REGULATORY FACTOR 1; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; MDS1 AND EVI1 COMPLEX LOCUS PROTEIN; RETINOIC ACID; STAT1 PROTEIN; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR RUNX1; CCAAT ENHANCER BINDING PROTEIN; CEBPA PROTEIN, HUMAN; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; TUMOR PROTEIN;

ACUTE MYELOID LEUKEMIA; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL MEMBRANE PERMEABILITY; CELL VIABILITY; CONTROLLED STUDY; DEREGULATION; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GENE MUTATION; HISTONE METHYLATION; HL-60 CELL LINE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; MOUSE; MYELOPOIESIS; NONHUMAN; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR VOLUME; AMINO ACID SUBSTITUTION; ANIMAL; BLAST CRISIS; CELL SURVIVAL; CLINICAL TRIAL; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; GENETICS; GRANULOCYTE; LEUKEMIA, MYELOID, ACUTE; MALE; METABOLISM; MISSENSE MUTATION; MULTICENTER STUDY; NUDE MOUSE; PATHOLOGY;

AMINO ACID SUBSTITUTION; ANIMALS; BLAST CRISIS; CCAAT-ENHANCER-BINDING PROTEINS; CELL DIFFERENTIATION; CELL SURVIVAL; FEMALE; GRANULOCYTES; HL-60 CELLS; HUMANS; ISOCITRATE DEHYDROGENASE; LEUKEMIA, MYELOID, ACUTE; MALE; MICE; MICE, NUDE; MUTATION, MISSENSE; NEOPLASM PROTEINS; TRETINOIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84993496439     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20150736     Document Type: Article

References (37)

1. Abbas, S., S. Lugthart, F.G. Kavelaars, A. Schelen, J.E. Koenders, A. Zeilemaker, W.J. van Putten, A.W. Rijneveld, B. Löwenberg, and P.J. Valk. 2010. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood. 116:2122-2126. http://dx.doi.org/10.1182/blood-2009-11-250878
2. Altucci, L., A. Rossin, O. Hirsch, A. Nebbioso, D. Vitoux, E. Wilhelm, F. Guidez, M. De Simone, E.M. Schiavone, D. Grimwade, et al. 2005. Rexinoid-triggered differentiation and tumor-selective apoptosis of acute myeloid leukemia by protein kinase A-mediated desubordination of retinoid X receptor. Cancer Res. 65:8754-8765. http://dx.doi.org/10.1158/0008-5472.CAN-04-3569
3. Bagger, F.O., N. Rapin, K. Theilgaard-Mönch, B. Kaczkowski, L.A. Thoren, J. Jendholm, O. Winther, and B.T. Porse. 2013. HemaExplorer: a database of mRNA expression profiles in normal and malignant haematopoiesis. Nucleic Acids Res. 41(D1):D1034-D1039. http://dx.doi.org/10.1093/nar/gks1021
4. Burnett, A.K., R.K. Hills, C. Green, S. Jenkinson, K. Koo, Y. Patel, C. Guy, A. Gilkes, D.W. Milligan, A.H. Goldstone, et al. 2010. The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEB PA. Blood. 115:948-956. http://dx.doi.org/10.1182/blood-2009-08-236588
5. Chan, S.M., D. Thomas, M.R. Corces-Zimmerman, S. Xavy, S. Rastogi, W.J. Hong, F. Zhao, B.C. Medeiros, D.A. Tyvoll, and R. Majeti. 2015. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat. Med. 21:178-184. http://dx.doi.org/10.1038/nm.3788
6. Chelbi-Alix, M.K., and L. Pelicano. 1999. Retinoic acid and interferon signaling cross talk in normal and RA-resistant APL cells. Leukemia. 13:1167-1174. http://dx.doi.org/10.1038/sj.leu.2401469
7. Chou, A.P., R. Chowdhury, S. Li, W. Chen, A.J. Kim, D.E. Piccioni, J.M. Selfridge, R.R. Mody, S. Chang, S. Lalezari, et al. 2012. Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas. J. Natl. Cancer Inst. 104:1458-1469. http://dx.doi.org/10.1093/jnci/djs357
8. Dang, L., D.W. White, S. Gross, B.D. Bennett, M.A. Bittinger, E.M. Driggers, V.R. Fantin, H.G. Jang, S. Jin, M.C. Keenan, et al. 2009. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 462:739-744. http://dx.doi.org/10.1038/nature08617
9. DiNardo, C.D., K.J. Propert, A.W. Loren, E. Paietta, Z. Sun, R.L. Levine, K.S. Straley, K. Yen, J.P. Patel, S. Agresta, et al. 2013. Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood. 121:4917-4924. http://dx.doi.org/10.1182/blood-2013-03-493197
10. Dos Santos, C., C. Demur, V. Bardet, N. Prade-Houdellier, B. Payrastre, and C. Récher. 2008. A critical role for Lyn in acute myeloid leukemia. Blood. 111:2269-2279. http://dx.doi.org/10.1182/blood-2007-04-082099
11. Fathi, A.T., H. Sadrzadeh, A.H. Comander, M.J. Higgins, A. Bardia, A. Perry, M. Burke, R. Silver, C.R. Matulis, K.S. Straley, et al. 2014. Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate. Oncologist. 19:602-607. http://dx.doi.org/10.1634/theoncologist.2013-0417
12. Ferrari-Amorotti, G., K. Keeshan, M. Zattoni, C. Guerzoni, G. Iotti, S. Cattelani, N.J. Donato, and B. Calabretta. 2006. Leukemogenesis induced by wild-type and STI571-resistant BCR/ABL is potently suppressed by C/EBPa. Blood. 108:1353-1362. http://dx.doi.org/10.1182/blood-2006-01-011833
13. Figueroa, M.E., O. Abdel-Wahab, C. Lu, P.S. Ward, J. Patel, A. Shih, Y. Li, N. Bhagwat, A. Vasanthakumar, H.F. Fernandez, et al. 2010a. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 18:553-567. http://dx.doi.org/10.1016/j.ccr.2010.11.015
14. Figueroa, M.E., S. Lugthart, Y. Li, C. Erpelinck-Verschueren, X. Deng, P.J. Christos, E. Schifano, J. Booth, W. van Putten, L. Skrabanek, et al. 2010b. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell. 17:13-27. http://dx.doi.org/10.1016/j.ccr.2009.11.020
15. Green, C.L., C.M. Evans, L. Zhao, R.K. Hills, A.K. Burnett, D.C. Linch, and R.E. Gale. 2011. The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood. 118:409-412. http://dx.doi.org/10.1182/blood-2010-12-322479
16. Guilhamon, P., M. Eskandarpour, D. Halai, G.A. Wilson, A. Feber, A.E. Teschendorff, V. Gomez, A. Hergovich, R. Tirabosco, M. Fernanda Amary, et al. 2013. Meta-analysis of IDH-mutant cancers identifies EBF1. as an interaction partner for TET2. Nat. Commun. 4:2166. http://dx.doi.org/10.1038/ncomms3166
17. Hasemann, M.S., F.K. Lauridsen, J. Waage, J.S. Jakobsen, A.K. Frank, M.B. Schuster, N. Rapin, F.O. Bagger, P.S. Hoppe, T. Schroeder, and B.T. Porse. 2014. C/EBPa is required for long-term self-renewal and lineage priming of hematopoietic stem cells and for the maintenance of epigenetic configurations in multipotent progenitors. PLoS Genet. 10:e1004079. http://dx.doi.org/10.1371/journal.pgen.1004079
18. Janin, M., E. Mylonas, V. Saada, J.B. Micol, A. Renneville, C. Quivoron, S. Koscielny, L. Scourzic, S. Forget, C. Pautas, et al. 2014. Serum 2-hydroxyglutarate production in IDH1-and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group. J. Clin. Oncol. 32:297-305. http://dx.doi.org/10.1200/JCO.2013.50.2047
19. Kats, L.M., M. Reschke, R. Taulli, O. Pozdnyakova, K. Burgess, P. Bhargava, K. Straley, R. Karnik, A. Meissner, D. Small, et al. 2014. Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance. Cell Stem Cell. 14:329-341. http://dx.doi.org/10.1016/j.stem.2013.12.016
20. Kernytsky, A., F. Wang, E. Hansen, S. Schalm, K. Straley, C. Gliser, H. Yang, J. Travins, S. Murray, M. Dorsch, et al. 2015. IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by smallmolecule inhibition. Blood. 125:296-303. http://dx.doi.org/10.1182/blood-2013-10-533604
21. Laiosa, C.V., M. Stadtfeld, and T. Graf. 2006. Determinants of lymphoidmyeloid lineage diversification. Annu. Rev. Immunol. 24:705-738. http://dx.doi.org/10.1146/annurev.immunol.24.021605.090742
22. Losman, J.A., R.E. Looper, P. Koivunen, S. Lee, R.K. Schneider, C. McMahon, G.S. Cowley, D.E. Root, B.L. Ebert, and W.G. Kaelin Jr. 2013. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science. 339:1621-1625. http://dx.doi.org/10.1126/science.1231677
23. Lu, C., P.S. Ward, G.S. Kapoor, D. Rohle, S. Turcan, O. Abdel-Wahab, C.R. Edwards, R. Khanin, M.E. Figueroa, A. Melnick, et al. 2012. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 483:474-478. http://dx.doi.org/10.1038/nature10860
24. Mardis, E.R., L. Ding, D.J. Dooling, D.E. Larson, M.D. McLellan, K. Chen, D.C. Koboldt, R.S. Fulton, K.D. Delehaunty, S.D. McGrath, et al. 2009. Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 361:1058-1066. http://dx.doi.org/10.1056/NEJMoa0903840
25. Matsuo, Y., R.A. MacLeod, C.C. Uphoff, H.G. Drexler, C. Nishizaki, Y. Katayama, G. Kimura, N. Fujii, E. Omoto, M. Harada, and K. Orita. 1997. Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23). Leukemia. 11:1469-1477. http://dx.doi.org/10.1038/sj.leu.2400768
26. Nazha, A., C. Bueso-Ramos, E. Estey, S. Faderl, S. O'Brien, M.H. Fernandez, M. Nguyen, C. Koller, E. Freireich, M. Beran, et al. 2013. The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia. Front. Oncol. 3:218. http://dx.doi.org/10.3389/fonc.2013.00218
27. Radomska, H.S., C.S. Huettner, P. Zhang, T. Cheng, D.T. Scadden, and D.G. Tenen. 1998. CCA AT/enhancer binding protein a is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors. Mol. Cell. Biol. 18:4301-4314. http://dx.doi.org/10.1128/MCB.18.7.4301
28. Sakashita, A., T. Nakamaki, N. Tsuruoka, Y. Honma, and M. Hozumi. 1991. Granulocyte colony-stimulating factor, not granulocyte-macrophage colony-stimulating factor, co-operates with retinoic acid on the induction of functional N-formyl-methionyl-phenylalanine receptors in HL-60 cells. Leukemia. 5:26-31
29. Sasaki, M., C.B. Knobbe, J.C. Munger, E.F. Lind, D. Brenner, A. Brüstle, I.S. Harris, R. Holmes, A. Wakeham, J. Haight, et al. 2012. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature. 488:656-659. http://dx.doi.org/10.1038/nature11323
30. + stem/progenitor cells impairs self-renewal and partially restores myelopoiesis. Blood. 110:1317-1325. http://dx.doi.org/10.1182/blood-2006-10-052175
31. Schlenk, R.F., K. Döhner, M. Kneba, K. Götze, F. Hartmann, F. Del Valle, H. Kirchen, E. Koller, J.T. Fischer, L. Bullinger, et al. German-Austrian AML Study Group (AML SG). 2009. Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AML SG Trial AML HD98B. Haematologica. 94:54-60. http://dx.doi.org/10.3324/haematol.13378
32. Shen, M., R.P. Bunaciu, J. Congleton, H.A. Jensen, L.G. Sayam, J.D. Varner, and A. Yen. 2011. Interferon regulatory factor-1 binds c-Cbl, enhances mitogen activated protein kinase signaling and promotes retinoic acidinduced differentiation of HL-60 human myelo-monoblastic leukemia cells. Leuk. Lymphoma. 52:2372-2379. http://dx.doi.org/10.3109./10428194.2011.603449
33. Shlush, L.I., S. Zandi, A. Mitchell, W.C. Chen, J.M. Brandwein, V. Gupta, J.A. Kennedy, A.D. Schimmer, A.C. Schuh, K.W. Yee, et al. HALT Pan-Leukemia Gene Panel Consortium. 2014. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature. 506:328-333. http://dx.doi.org/10.1038/nature13038
34. Turcan, S., D. Rohle, A. Goenka, L.A. Walsh, F. Fang, E. Yilmaz, C. Campos, A.W. Fabius, C. Lu, P.S. Ward, et al. 2012. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 483:479-483. http://dx.doi.org/10.1038/nature10866
35. Verhaak, R.G., B.J. Wouters, C.A. Erpelinck, S. Abbas, H.B. Beverloo, S. Lugthart, B. Löwenberg, R. Delwel, and P.J. Valk. 2009. Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. Haematologica. 94:131-134. http://dx.doi.org/10.3324/haematol.1329918838472
36. Wang, F., J. Travins, B. DeLaBarre, V. Penard-Lacronique, S. Schalm, E. Hansen, K. Straley, A. Kernytsky, W. Liu, C. Gliser, et al. 2013a. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science. 340:622-626. http://dx.doi.org/10.1126/science.1234769
37. Wang, J.H., W.L. Chen, J.M. Li, S.F. Wu, T.L. Chen, Y.M. Zhu, W.N. Zhang, Y. Li, Y.P. Qiu, A.H. Zhao, et al. 2013b. Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China. Proc. Natl. Acad. Sci. USA. 110:17017-17022. http://dx.doi.org/10.1073/pnas.1315558110